Search results
Results from the WOW.Com Content Network
Megaloblastic anaemia; Methaemoglobinaemia; Erythema multiforme; Low blood sugar; Hepatitis (liver swelling); Crystalluria (crystals in the urine); Urinary obstruction causing difficulty passing urine
Adverse effects occur in fewer than 1% of patients and include muscle weakness, headache, arterial hypotension, nausea, vomiting, dyspepsia, and dry mouth. All effects are reversible. [3] [4] Allergic reactions occur in fewer than 0.1% of patient and include skin rash, hives, Quincke's edema, and in some cases anaphylactic shock. [3] [7] [8] [9]
Many patients will not develop these side effects, although there is still a significant possibility of risks associated with Antipsychotic usage. The percentage of patients affected by side effects like Tardive dyskinesia is significantly high and estimated to be a 20-50% prevalence. [1] [2]
There are no known long-term side effects of tadalafil. ... no more than once per 72 hours — or a daily dosage of 2.5 milligrams — if you’re prescribed any other medication that inhibits ...
Threshold dose is a dose of drug barely adequate to produce a biological effect in an animal. In dose-response assessment, the term ‘threshold dose’ is refined into several terminologies, such as NOEL, NOAEL, and LOAEL. They define the limits of doses resulting in biological responses or toxic effects. [3]
In clinical trials supported by Novo Nordisk, gallstones were reported in 1.5 percent of people taking a 0.5-milligram dose of Ozempic and 0.4 percent of those taking 1 milligram of Ozempic ...
[25] [26] However, since the correlation between long-term use of potent topical glucocorticoid in pregnant women and low birth weight cannot be neglected, pregnant women who require topical glucocorticoids should be administered with low- or medium-potency agents instead of potent or superpotent ones. If potent or superpotent topical ...
Histamine dihydrochloride is administered in conjunction with low doses of the immune-activating cytokine interleukin-2 (IL-2) in the post-remission phase of AML, i.e. when patients have completed the initial chemotherapy. This combination has been reported to significantly reduce the risk of relapse in AML. [4]